Quanming Zhao

Dr. Quanming Zhao


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 February 2020 in Cell Biochemistry and Function
Verified
Journal Article
Closed access
PDF file
XZXiao‐Xia Zhang
Xiao‐Xia Zhang
XWXue‐Si Wu
Xue‐Si Wu
SMShu‐Hua Mi
Shu‐Hua Mi
SFShan‐Juan Fang
Shan‐Juan Fang
SLSa Liu
Sa Liu
QZQuanming Zhao
Quanming Zhao

22 October 2020 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
ZLZhe Liang
Zhe Liang
QCQi Chen
Qi Chen
FYFei Yang
Fei Yang
XYXianliang Yan
Xianliang Yan
XZXuehui Zhang
Xuehui Zhang
QZQuanming Zhao
Quanming Zhao

21 August 2019 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
YYYunfeng Yan
Yunfeng Yan
MZMingduo Zhang
Mingduo Zhang
FYFei Yuan
Fei Yuan
HLHong Liu
Hong Liu
DWDi Wu
Di Wu
SLShuzheng Lyu
Shuzheng Lyu
The territory of the right coronary artery (RCA) is smaller than that of the left anterior descending artery. Previous studies have reported conflicting results when considering whether stable RCA-chronic total occlusion (CTO) should be reopened. The coexistence of diabetic and coronary artery diseases represents a severe situation. Therefore, we aimed to determine if stable RCA-CTO in diabetic patients was necessary to be reopened. To our knowledge, no studies have focused on this topic to date. We enrolled diabetic patients with RCA-CTO who had clinical presentations of symptomatic stable angina or silent ischemia. RCA-CTO was treated with either successful revascularization (the CTO-SR group) or medical therapy (the CTO-MT group). The primary endpoint was all-cause death. Both Cox regression and propensity score matching analyses were used. Sensitivity analysis was performed based on subgroup populations and relevant baseline variables. A total of 943 patients were included: 443 (46.98%) patients in the CTO-MT group and 500 (53.02%) patients in the CTO-SR group. After a mid-term follow-up (CTO-SR: 48 months; CTO-MT: 42 months), we found that CTO-SR was superior to CTO-MT in terms of all-cause death (adjusted hazard ratio [HR] [model 1]: 0.429, 95% conference interval [CI] 0.269–0.682; adjusted HR [model 2]: 0.445, 95% CI 0.278–0.714). The superiority of CTO-SR was consistent for cardiac death, possible/definite cardiac death, repeat revascularization, target vessel revascularization (TVR) and repeat nonfatal myocardial infarction. Subgroup analysis confirmed the mortality benefit of CTO-SR by percutaneous coronary intervention (the successful CTO-PCI subgroup, 309 patients in total). While CTO-SR by coronary artery bypass grafting (the CTO-CABG subgroup, 191 patients in total) offered patients more benefit from repeat revascularization and TVR than that offered by successful CTO-PCI. For stable RCA-CTO patients with diabetes, successful revascularization offered patients more clinical benefits than medical therapy. CTO-CABG might be a more recommended way to accomplish revascularization. Trial registration This study was not registered in an open access database

14 April 2021 in Frontiers in Pharmacology
Verified
Journal Article
Open access
PDF file
ZLZhe Liang
Zhe Liang
QCQi Chen
Qi Chen
RWRuiqi Wei
Ruiqi Wei
CMChenyao Ma
Chenyao Ma
XZXuehui Zhang
Xuehui Zhang
QZQuanming Zhao
Quanming Zhao
Background: Proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab reduce ischemic events; however, the cost-effectiveness remains uncertain. This study sought to evaluate its economic value in patients with myocardial infarction (MI) from the Chinese healthcare perspective.Methods: A state-transition Markov model was developed to determine the cost-effectiveness of alirocumab for preventing recurrent MI, ischemic stroke and death. Preventative effect of the therapy was gathered from ODYSSEY OUTCOMES trial and absolute reduction of low-density lipoprotein cholesterol (LDL-C) in ODYSSEY EAST trial, respectively. The primary outcome was the incremental cost-effectiveness ratio (ICER), defined as incremental cost per quality-adjusted life-year (QALY) gained.Results: Compared with statin monotherapy, the ICER of alirocumab therapy at its present discounted price [34,355 Chinese yuan (CNY) annually, 33% rebate] based on clinical follow-up efficacy was 1,613,997 CNY per QALY gained. A willingness-to-pay threshold of 212,676 CNY per QALY would be achieved when the annual cost of alirocumab was reduced by 88% from the full official price to 6071 CNY. The therapeutic effect evaluation estimated by the magnitude of LDL-C reduction was superior to the results of clinical follow-up, but this medication was still far from cost-effective. Multiple vulnerable subgroup analyses demonstrated that the ICER for patients with polyvascular disease in 3 vascular beds was 111,750 CNY per QALY gained.Conclusion: Alirocumab is not cost-effective in general MI population based on current discounted price. High long-term costs of alirocumab may be offset by health benefit in patients with polyvascular disease (3 beds).

27 September 2017 in Herz
Verified
Journal Article
Closed access
PDF file
JXJ. Xu
J. Xu
MNM. Nie
M. Nie
JLJ. Li
J. Li
ZXZ. Xu
Z. Xu
MZM. Zhang
M. Zhang
QZQuanming Zhao
Quanming Zhao

25 April 2022 in Cardiovascular Drugs and Therapy
Verified
Journal Article
Closed access
PDF file
XXXiaoyu Xi
Xiaoyu Xi
XWXin Wang
Xin Wang
WXWenwen Xie
Wenwen Xie
YJYu Jia
Yu Jia
SSSantiago Zuluaga Sanchez
Santiago Zuluaga Sanchez
QZQuanming Zhao
Quanming Zhao